Probe • Vol LXII • No. 4 • Sep–Dec 2023 • 3 Effect of Diabecon on Blood Sugar Level Procedures in alloxan-induced diabetic rats Effect of Diabecononblood sugar andurine sugar levels The FBS level was analyzed in 16 female rats, and they were then administered alloxan monohydrate intravenously at a dose of 50 mg/kg body weight. Of the 16 rats, only 12 rats responded to alloxan monohydrate, and they were divided into 2 groups of diabetic rats (6 in each). Group 1 was given tap water at a dosage of 10 mg/kg body weight, once a day, orally, for 42 days, and group 2 was given Diabecon at a dose of 2 g/kg body weight. The FBS and fasting urine sugar level were monitored on day 20, 30, and 40. On day 42, the rats were killed to estimate the liver glycogen. Interactionwith insulin After confirmation of stable alloxan-induced hyperglycemia on day 8, 6 rats were administered 0.5 IU of insulin, intravenously. The BSL was determined at 30, 60, 90, 120, 180, and 240 minutes. Diabecon was administered at a dosage of 2 g/kg body weight, once a day, orally, for 21 days, and the BSL was analyzed at the same time periods. Results In normoglycemic rats • On day 30, the aqueous suspension of Diabecon exerted a significant hypoglycemic effect in both male and female rats (P < .005). There was no further decrease in the BSL after 90 days of treatment. • The hyperglycemic response to adrenaline was significantly reduced at 120 and 180 minutes following Diabecon administration (P < .05). • Tolbutamide decreased the BSL at the second hour and normalized it at the fourth hour, while treatment with Diabecon for 21 days decreased the BSL at the third and fourth hours (P < .05). • Treatment with Diabecon caused a decrease in BSL, similar to insulin, in normoglycemic rats. In alloxan-induced diabetic rats • Treatment with Diabecon caused a significant decrease in the FBS and urinary sugar level on days 20, 30, and 40 (Figure). Figure. The Mean FBS (mg%) Levels on Days 20, 30, and 40 Following Treatment With Diabecon in Alloxan-Induced Diabetic Rats FBS, fasting blood sugar. • In hyperglycemic rats, treatment with Diabecon significantly potentiated the hypoglycemic effect of insulin at 90, 120, 180, and 240 minutes. Conclusion The study findings suggest that Diabecon acts through several mechanisms. Treatment with Diabecon causes an improvement in insulin receptor responsiveness, leading to the enhanced uptake of glucose by tissues. Summary • The effects of Diabecon on blood sugar level (BSL) in normoglycemic rats and in alloxan-induced diabetic rats were evaluated in this study. • Four procedures were performed in normoglycemic rats, and 2 procedures were performed in alloxan-induced diabetic rats. • Diabecon exhibits a small but significant hypoglycemic effect in normoglycemic rats. • In hyperglycemic rats, treatment with Diabecon significantly potentiated the hypoglycemic effect of insulin. • In hyperglycemic rats, the hypoglycemic effect of insulin was enhanced, and the liver glycogen store was significantly higher following treatment with Diabecon. 400 200 100 300 Control Diabecon P < .05 0 Mean FBS, mg% Basal 72 h After Alloxan Day 20 Day 30 Day 40
RkJQdWJsaXNoZXIy MjAwNDg=